Peptides won the vote – what happens now?
Former FDA officer Abha Kundi explains what the peptide vote changes, what it does not – and where clinics face risk. Two weeks after an FDA advisory committee delivered a striking series of votes in favor of compounded peptide access, the dust has settled a little – although the regulatory position
<p>Former FDA officer Abha Kundi explains what the peptide vote changes, what it does not – and where clinics face risk. Two weeks after an FDA advisory committee delivered a striking series of votes in favor of compounded peptide access, the dust has settled a little – although the regulatory position</p>